aibio
Mergers ·
Hepion acquires Gravitas Life Sciences in a related party deal
The purchase closed October 6, 2026 for $2,000,000 in cash and 25,000,000 shares, and four directors have ties to the seller's group.
HEPA Hepion Pharmaceuticals, Inc.
Hepion Pharmaceuticals (HEPA) news HEPA delisting, offering and convertible notes news
Latest Hepion Pharmaceuticals news
- Debt Financing
Hepion Pharmaceuticals issues $500,000 secured convertible note to Gravitas
The note bears 8% interest payable in kind and matures September 3, 2027. It converts at $0.04 per share after stockholders approve more authorized shares.
- Financings
Hepion sells 8,000,000 shares and warrants in a $400,000 private placement
The agreements are dated August 25, 2026, and priced at $0.05 per share. The filing names no underwriter or placement agent.
- Company Updates
Hepion appoints James Liddy as a director
The board approved the appointment on August 19, 2026, effective immediately. The filing says no arrangements tie his selection to any other person.
- Financings
Hepion closes $3,055,000 private placement with matching warrants
Agreements dated July 31, 2026 cover 61,100,000 shares at $0.05 per share. The offering closed on August 3, 2026, and the filing names no underwriter.
- Company Updates
Hepion adds two directors, including the son of its interim CEO
Danina Fisher and Gary S. Stetz, II joined the board on July 1, 2026. The filing notes that Mr. Stetz is the son of Gary Stetz, the interim chief executive.
- Financings
Hepion raises $700,000 in a common stock private placement
The agreements dated April 21, 2026 cover 17,500,000 shares at $0.04 per share, and the offering closed the same day. The filing names no underwriter or placement agent.
- Company Updates
Hepion signs separation agreement with former CEO Kaouthar Lbiati
The April 13, 2026 agreement provides $225,000 and a pro-rata bonus of $30,625, plus six months of COBRA reimbursement. Dr. Lbiati also left the board that day.
- Distress
Hepion Pharmaceuticals delays quarterly report for three months ended March 31, 2025
Hepion says it is still compiling information for its March quarter 10-Q and expects to file within five calendar days. The notice previews research and development spending of $22,235, down from $2.5 million.
- Listings
Nasdaq panel delists Hepion Pharmaceuticals; company expects OTC quotation
Nasdaq's hearings panel decided to delist Hepion after it failed the $1.00 minimum bid price and Nasdaq said it believes the company is a public shell. Trading was set to stop on May 13, 2025, and Hepion expects its shares to quote on the OTC Markets.
What Hepion Pharmaceuticals does
Hepion Pharmaceuticals, Inc. is a medical diagnostic company headquartered in Morristown, New Jersey. It was previously focused on developing drug therapy for chronic liver diseases with rencofilstat, a cyclophilin inhibitor. The company began wind-down activities in its ASCEND-NASH trial in April 2024 because it did not have sufficient funding to complete the study, and the trial closed in August 2024. In May 2025 it entered a license agreement with New Day Diagnostics LLC for diagnostic tests for celiac disease, respiratory multiplex (Covid/Influenza A/B and RSV), Helicobacter pylori and hepatocellular carcinoma. The celiac, respiratory multiplex and H. pylori tests have CE marks and are eligible for sale in the European Union and certain other markets, but not currently in the United States. In May 2025 it sold its rencofilstat patent assets to Panetta Partners Limited for a nominal amount, and in February 2026 it licensed liver disease diagnostic assets from Cirna Diagnostics, LLC. The company says it has no commercialization or sales and marketing capabilities and owns no manufacturing facilities.
| Product or program | What it is | Stage |
|---|---|---|
| Celiac disease test | In-licensed diagnostic test from New Day Diagnostics | CE marked; not eligible for US sale at present |
| Respiratory multiplex test | Covid, Influenza A/B and RSV diagnostic test | CE marked; not eligible for US sale at present |
| H. pylori test | Helicobacter pylori diagnostic test | CE marked; not eligible for US sale at present |
| Hepatocellular carcinoma test | In-licensed diagnostic test for hepatocellular carcinoma | |
| Liver disease diagnostic assets | Intellectual property licensed from Cirna Diagnostics | licensed February 2026 |
Hepion Pharmaceuticals annual financials
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $445,512 | $11.8 million |
| Net income (loss) | -$8.3 million | -$13.2 million |
| Cash from operations | -$3.3 million | -$18.2 million |
| Cash and equivalents | $1.8 million | $406,408 |
Questions about Hepion Pharmaceuticals
Was Hepion Pharmaceuticals delisted?
Our latest story on this, dated May 12, 2025: "Nasdaq panel delists Hepion Pharmaceuticals; company expects OTC quotation". The story links the filing or release it is based on. Read the story.
Has Hepion Pharmaceuticals raised money recently?
Our latest story on this, dated Aug 25, 2026: "Hepion sells 8,000,000 shares and warrants in a $400,000 private placement". The story links the filing or release it is based on. Read the story.
Has Hepion Pharmaceuticals sold convertible notes?
Our latest story on this, dated Sep 3, 2026: "Hepion Pharmaceuticals issues $500,000 secured convertible note to Gravitas". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Hepion Pharmaceuticals?
Hepion Pharmaceuticals, Inc. trades under the ticker HEPA on OTC.
Where is Hepion Pharmaceuticals listed?
Hepion Pharmaceuticals, Inc. is listed on OTC.
What is the SEC CIK of Hepion Pharmaceuticals?
The SEC Central Index Key (CIK) for Hepion Pharmaceuticals, Inc. is 1583771. Its filings are on SEC EDGAR.
How many shares does Hepion Pharmaceuticals have outstanding?
90,219,317 shares as of 2026-08-10, per the cover page of its 10-Q filed 2026-08-13.
Which country or territory is Hepion Pharmaceuticals listed under?
Our directory records Hepion Pharmaceuticals, Inc. under United States.
What does Hepion Pharmaceuticals do?
Our directory classifies Hepion Pharmaceuticals, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
What is the ISIN of Hepion Pharmaceuticals?
The ISIN recorded for Hepion Pharmaceuticals, Inc. is US4268974015.
Does aibio.space cover Hepion Pharmaceuticals?
aibio.space lists Hepion Pharmaceuticals, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Hepion Pharmaceuticals incorporated?
SEC records list its state or country of incorporation as DE.
What does Hepion Pharmaceuticals develop?
Hepion Pharmaceuticals, Inc. is a medical diagnostic company headquartered in Morristown, New Jersey. It was previously focused on developing drug therapy for chronic liver diseases with rencofilstat, a cyclophilin inhibitor.
What is Celiac disease test from Hepion Pharmaceuticals?
Celiac disease test: In-licensed diagnostic test from New Day Diagnostics Stage: CE marked; not eligible for US sale at present.
What is Respiratory multiplex test from Hepion Pharmaceuticals?
Respiratory multiplex test: Covid, Influenza A/B and RSV diagnostic test Stage: CE marked; not eligible for US sale at present.
Investor discussion: Hepion Pharmaceuticals
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
- Mergers
Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 1.01,2.01,3.02,5.02,9.01). Source
- Legal
Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). Source
- Financings
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,2.03,3.02,9.01). Source
- Distress
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
- Listings
Filed to remove its shares from exchange listing. SEC Form 25-NSE. Source
- Listings
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
- Distress
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). Source
- Financings
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02). Source
- Listings
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
- Listings
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
- Distress
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
- Distress
Told the SEC a periodic report would be filed late. SEC Form NT 10-K. Source
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
- Listings
Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,9.01). Source
- Listings
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
- Listings
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
- Listings
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
- Financings
Filed a final prospectus for a securities offering. SEC Form 424B4. Source
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
- Financings
Filed a registration statement for a share offering. SEC Form S-1. Source
- Distress
Reported the end of a material agreement. SEC Form 8-K (Items 1.02,8.01,9.01). Source
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
- Mergers
Filed documents for a merger or acquisition. SEC Form 425. Source
Stock chart
SEC filings and registration
- SEC name
- Hepion Pharmaceuticals, Inc.
- CIK
- 1583771
- Industry (SIC)
- Pharmaceutical Preparations (2834)
- US tickers
- HEPA (OTC), CTRVP (OTC)
- State or country of incorporation
- DE
- Fiscal year ends
- December 31
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Business address
- 34 SHREWSBURY AVE., RED BANK, NJ, 07701
- Phone
- 732-902-4000
- Shares outstanding
- 90,219,317 as of 2026-08-10 (10-Q filed 2026-08-13)
- Former names
- ContraVir Pharmaceuticals, Inc.
Recent filings
Listing details
- Company
- Hepion Pharmaceuticals, Inc.
- Ticker
- HEPA
- Listing
- OTC
- Country or territory
- United States
- Business scope
- Pharmaceuticals: Major
- ISIN
- US4268974015
- Last quote in directory
- 2026-10-21
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction